All In Biotech

Drug Trial Radar · NCT05513560

RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

REcovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM)

Last checked: Nov 19, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

460

Actual

Start

May 31, 2023

Primary completion

Mar 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
University Health Network, TorontoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers propose to develop a Canada-wide, adaptive randomized clinical platform trial to assess the effectiveness of various interventions in patients with lingering symptoms of COVID-19 ("Long COVID"). Participants will be randomized initially to 1 of 3 arms, including placebo (control) and 2 interventions. Because this is an adaptive trial, arms can be dropped if found to be ineffective and new arms can be added. Interventions will last for 2 months and participants will be followed for an additional 4 months (6 months total). Approximately 800-1000 patients with Long COVID will be recruited across Canada. Results from this trial will accelerate the availability of high-quality, real-time evidence and solutions to enable Canada to improve the clinical care of patients with Long COVID.

Conditions

  • Long COVID
  • Post COVID Condition
  • Post Acute Sequelae of COVID-19

Interventions

  • IbudilastDrug

    10mg pills, 2 pills twice per day

  • PentoxifyllineDrug

    400mg pill 3 times per day

  • PlaceboOther

    Placebo matching ibudilast, 2 pills twice per day OR placebo matching pentoxifylline 1 pill 3 time per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SF-36 physical component score (PCS)Time frame: from baseline to two months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • University Health Network, Osteoporosis Department

    Toronto, Ontario, Canada

  • Mount Sinai Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.